GlassScriptPhysician profile
Tarec Elajami
NPI 1174066005
$6,185.70
in general payments reported to CMS, 2019-2025
32 companies · $1,402 in 2025
The $1,402 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,500 · 2020: $228 · 2021: $1,771 · 2022: $431 · 2023: $317 · 2024: $537 · 2025: $1,402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,255.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $893.47 | 2021-2025 | Watchman Flx, General - Therapies |
| Astellas Pharma US INC | $756.14 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $448.49 | 2019-2021 | |
| Abbott Laboratories | $402.30 | 2021-2023 | Pressurewire, Cardiomems |
| Heartflow, INC. | $324.90 | 2025 | |
| Novartis Pharmaceuticals Corporation | $306.74 | 2019-2025 | |
| Pfizer INC. | $304.86 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $294.30 | 2019-2025 | Wainua, Brilinta |
| Medtronic, INC. | $269.96 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $259.17 | 2019-2023 | Lifevest |
| Viiv Healthcare Company | $245.25 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $226.22 | 2022-2024 | Uptravi, Opsumit |
| Amgen INC. | $216.00 | 2021-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $159.42 | 2021-2024 | |
| Zoll Circulation INC | $147.60 | 2023 | Catheter, Downstream Cartridge, Therox Ds2 Console |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $124.99 | 2019 | |
| Amarin Pharma, INC. | $124.95 | 2019 | |
| Lilly USA, LLC | $121.00 | 2025 | Zepbound |
| E.R. Squibb & Sons, L.L.C. | $111.13 | 2021-2025 | Camzyos |
| Cleerly, INC. | $60.00 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Alexion Pharmaceuticals, INC. | $52.19 | 2021 | |
| Celltrion USA INC. | $44.28 | 2025 | Vegzelma |
| Bayer Healthcare Pharmaceuticals INC. | $38.87 | 2025 | |
| Novo Nordisk INC | $37.56 | 2025 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.83 | 2022 | |
| Alnylam Pharmaceuticals INC. | $31.58 | 2025 | Amvuttra |
| Terumo Medical Corporation | $28.67 | 2020 | |
| Glaxosmithkline, LLC. | $27.29 | 2025 | Shingrix, Arexvy |
| Philips North America LLC | $26.75 | 2025 | Diagnostic Ecg Service |
| Myriad Genetic Laboratories, INC. | $24.29 | 2025 | Myrisk |
| Kiniksa Pharmaceuticals International, Plc | $21.41 | 2024 | Arcalyst |
| Melinta Therapeutics, LLC | $21.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarec Elajami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.